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Clinical managementA B S T R A C T
Aims: We aimed to briefly review the general characteristics of the novel coronavirus
(SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19)
in people with diabetes, and its management.
Methods: We searched for articles in PubMed and Google Scholar databases till 02 April
2020, with the following keywords: ‘‘SARS-CoV-2”, ‘‘COVID-19”, ‘‘infection”, ‘‘pathogenesis”,
‘‘incubation period”, ‘‘transmission”, ‘‘clinical features”, ‘‘diagnosis”, ‘‘treatment”,
‘‘diabetes”, with interposition of the Boolean operator ‘‘AND”.
Results: The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like
symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older
age, diabetes and other comorbidities are reported as significant predictors of morbidity
and mortality. Chronic inflammation, increased coagulation activity, immune response
impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the
underlying mechanisms of the association between diabetes and COVID-19. No conclusive
evidence exists to support the discontinuation of angiotensin-converting enzyme inhibi-
tors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in
people with diabetes. Caution should be taken to potential hypoglycemic events with the
use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glu-
cose monitoring and careful consideration of drug interactions might reduce adverse out-
comes.
Conclusions: Suggestions are made on the possible pathophysiological mechanisms of the
relationship between diabetes and COVID-19, and its management. No definite conclusions
can be made based on current limited evidence. Further research regarding this relation-
ship and its clinical management is warranted.
 2020 The Author(s). Published by Elsevier B.V. This is an open access articleunder theCCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Coronaviruses are enveloped, positive single-stranded RNA
viruses widely distributed in humans and animals worldwide
[1]. Although most human coronavirus infections are mild,
major outbreaks of two betacoronaviruses, severe acute respi-
ratory syndrome coronavirus (SARS-CoV) in 2002–2003 and
Middle East respiratory syndrome coronavirus (MERS-CoV)
in 2012, have caused deadly pneumonia, with mortality rates
of 10% for SARS-CoV and 36% for MERS-CoV [2].
In December 2019, clusters of pneumonia cases of unknown
etiology emerged in Wuhan, Hubei Province, China. Deep
sequencing analysis from lower respiratory tract samples indi-
cated a novel coronavirus as the causative agent, which was
named Severe Acute Respiratory Syndrome-Coronavirus-2
(SARS-CoV-2), and the disease it causes called COVID-19 [1,3].
Although SARS-CoV-2 has shown phylogenetic and clinical
similarities with SARS-CoV, the novel coronavirus appears to
have a higher transmissibility and lower case fatality rates [4].
On 30 January 2020, the World Health Organization (WHO)
declared the COVID-19 outbreak a Public Health Emergency of
International Concern, and on March 11, the epidemic was
upgraded to pandemic [5]. As of today (02.04.2020), 827,419 con-
firmed cases are officially reported in more than 200 countries
or territories with 40,777 deaths [6].
We conducted a scoping review to provide a brief summary
of the general characteristics of COVID-19, as well as a more
detailed description and critical assessment of the associa-
tion between this new infectious disease and diabetes. We
hope this review can provide meaningful information for
future research and ultimately contribute to better clinical
management of patients with COVID-19 and diabetes.2. Methods
A literature review was carried out to search for articles in
PubMed and Google Scholar databases till 02 April 2020. The
following keywords were used: ‘‘SARS-CoV-2”, ‘‘COVID-19”,
‘‘infection”, ‘‘pathogenesis”, ‘‘incubation period”, ‘‘transmis-
sion”, ‘‘clinical features”, ‘‘diagnosis”, ‘‘treatment”, ‘‘dia-
betes”, with interposition of the Boolean operator ‘‘AND”.
We also retrieved the full text of the relevant cross refer-
ences from the search results. Furthermore, we accessed
the currently available scientific literature and recommen-
dations in the WHO and United States Centers for Disease
Control and Prevention (CDC) websites.
3. General characteristics of COVID-19
3.1. Incubation period
The incubation period is described as the time from infection
to illness onset. In a study of 1099 patients from China with
laboratory-confirmed symptomatic COVID-19, the median
incubation period was four days (interquartile range, 2–7)
[7]. Another study including 181 confirmed cases reported a
median incubation period of approximately 5 days, and that
symptoms would develop in 97.5% of infected individuals
within 12 days [8]. Based on the incubation period of SARS-
CoV and MERS-CoV, as well as observational data, the United
States CDC has estimated that symptoms of COVID-19 will
usually develop within 2–14 days after exposure. Therefore,
fourteen days has been the time applied internationally for
monitoring and restricting the movement of healthy individ-
uals (quarantine period) [9].
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Most initial COVID-19 patients had a direct contact history
with a local Chinese seafood and wildlife market, suggesting
a common-source zoonotic exposure as the main mode of
transmission [10]. Findings from virus genome sequencing
analysis have pointed out that SARS-CoV-2 and bat coron-
avirus (bat CoV) might share the same ancestor, although bats
are not for sale in this seafood market [11]. Later cases were
reported among health care workers and others without
exposure history of wildlife or visiting Wuhan, which indi-
cated human-to-human transmission [10]. Currently, it is
considered that the virus can be mainly transmitted through
droplets, direct contact and aerosols. Droplets transmission
may occur when respiratory droplets, produced when an
infected person coughs or sneezes, are ingested or inhaled
by individuals nearby (within about 6 feet). A subject can also
get infected by touching a surface or object contaminated
with the virus and subsequently touching his/her mouth,
nose, or eyes [12]. Additionally, it has been shown experimen-
tally that the virus can remain viable in aerosols for at least
3 h [13], and can be transmitted in closed environments if
inhaled into the lungs [12]. Therefore, airborne transmission
is a possibility during aerosol generating procedures, e.g.,
endotracheal intubation, bronchoscopy, non-invasive
positive-pressure ventilation, tracheostomy, cardiopul-
monary resuscitation, etc [14]. Although viable virus has been
identified in fecal swabs, the fecal-oral route does not appear
to be a driver of COVID-19 transmission [11].
3.3. Period of infectivity
It is uncertain how long an individual with COVID-19 remains
infectious. The period of infectivity is often assessed indi-
rectly by detection of viral RNA from respiratory specimens.
However, viral RNA does not necessarily confirm the presence
of infectious virus. Higher viral loads have been detected soon
after symptom onset, suggesting that transmission may be
more likely to occur in the earlier stages of infection [15].
The viral shedding duration seems to vary according to the
disease severity. It has been found that around 90% of
patients with milder symptoms had a negative viral RNA test
on nasopharyngeal swabs by day 10 post-onset, while the test
remained positive for a longer time in all severe cases [16]. On
the other hand, it has been reported that the viral load
detected in asymptomatic patients was similar to that in
symptomatic subjects [15]. Indeed, transmission from asymp-
tomatic carriers or individuals within the incubation period
has been described [17]. Nevertheless, the extent to which
this occurs remains to be determined.
3.4. Demography and clinical characteristics
Even though all age groups have been affected by COVID-19,
the median age appears to be around 47–59 years, and usually
higher among severe cases and non-survivors. No specific
gender bias seems to exist for the contamination with the
virus, but men tend to have a higher propensity of the cases
[7,18,19]. Fewer cases have been identified among childrenand infants. In a large Chinese report including 72,314
patients, only 2% of those infectedwere younger than 20 years
old [20].
The clinical spectrum of COVID-19 can be very heteroge-
neous. Most adults and children present mild flu-like symp-
toms, but some may rapidly develop acute respiratory
distress syndrome (ARDS), respiratory failure, arrhythmias,
acute cardiac injury, shock, multiple organ failure and death
[1,18]. The most commonly reported symptoms are fever,
cough, fatigue, sputum production and shortness of breath.
However, headache, upper respiratory symptoms (e.g., sore
throat and rhinorrhea) and gastrointestinal symptoms
(e.g., nausea and diarrhea) occur less often [1,7,18].
Although not described in the initial Chinese studies, smell
and taste disorders (e.g., anosmia and dysgeusia) have also
been found frequently in patients with COVID-19 in Italy
[21].
In laboratory examination results, most patients have nor-
mal or decreased white blood cell counts, particularly lym-
phocytopenia [7]. However, in severe patients, the
neutrophil count, inflammatory markers, D-dimer, blood
urea, and creatinine levels are generally higher, with further
decreased lymphocyte counts [1]. Chest computed tomogra-
phy (CT) most commonly shows ground-glass opacifications
with or without consolidative abnormalities. They are also
more likely to be bilateral, have a peripheral distribution
and involve the lower lobes [7,22]. While some confirmed
cases may present normal CT images [11], abnormalities have
also been identified prior to the development of symptoms in
some patients [22].
3.5. Diagnosis
The diagnosis of COVID-19 cannot be made without microbi-
ologic analysis. Patients who meet the criteria discussed
below should undergo testing for SARS-CoV-2, in addition to
testing for other respiratory pathogens (e.g., influenza, respi-
ratory syncytial virus, etc). Since testing for COVID-19 in sus-
pected cases is limited owing to inadequate capacity, local
health authorities may introduce specific criteria for priority
cases [23]. Although many laboratory tests have been devel-
oped, real-time fluorescence (RT-PCR) has been the current
standard diagnostic method for diagnosis of COVID-19, by
detecting the positive nucleic acid of SARS-CoV-2 in sputum,
throat swabs, and secretions of the lower respiratory tract
samples [23,24].
3.5.1. Criteria for suspicion and testing
Community surveillance should be introduced in all countries
in order to register the new cases of COVID-19 and map the
transmission route. According to the WHO and other litera-
ture, the following is recommended [23,25]:
3.5.1.1. Preliminary symptoms for observations. Individuals
with new onset fever and/or respiratory tract symptoms (e.g.,
cough, dyspnea) or patients with severe lower respiratory
tract illness, without any clear cause and without any history
of close contact with a confirmed COVID-19 patient or have
travelled to an area of community transmission.
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resources. Subjects with new onset fever and/or respiratory
tract symptoms (e.g., cough, dyspnea) or patients with severe
lower respiratory tract illness, who have been in contact with
COVID-19 patients or travelled within 14 days to a location
where community transmission of SARS-CoV-2 is present.
Furthermore, patients older than 60 years of age, as well as
those with underlying conditions like diabetes, hypertension,
cardiovascular diseases (CVDs), chronic renal disease, cancer
and immunocompromising conditions, who develop symp-
toms of fever, cough and/or dyspnea should be prioritized
for testing.
3.5.1.3. Must be tested. Persons in close contact (within
2 m) with a SARS-CoV-2 infected individual for a prolonged
period or in direct contact with infectious secretions while
not wearing personal protective equipment.
3.6. COVID-19 and comorbidities
Although the pathophysiological mechanisms are still not
understood, it has been observed that most severe and fatal
cases with COVID-19 have occurred in the elderly or in
patients with underlying comorbidities, particularly CVDs,
diabetes mellitus, chronic lung and renal disease, hyperten-
sion, and cancer [7,20,26,27].
One Chinese meta-analysis including 1527 patients
showed that the most prevalent cardiovascular metabolic
comorbidities with COVID-19 were hypertension (17.1%, 95%
CI 9.9–24.4%) and cardio-cerebrovascular disease (16.4%, 95%
CI 6.6–26.1%), followed by diabetes (9.7%, 95% CI 6.9–12.5%).
In this report, patients with diabetes or hypertension had a
2-fold increase in risk of severe disease or requiring intensive
care unit (ICU) admission, while those with cardio-
cerebrovascular disease had a 3-fold increase [28]. In a sub-
set of 355 patients with COVID-19 in Italy who died, the mean
number of pre-existing underlying conditions was 2.7, and
only 3 subjects did not have any comorbidity [29].
It has been consistently reported that, in addition to pneu-
monia, SARS-CoV-2 may cause damage to other organs
including the heart, liver and kidneys [1,18]. Therefore, full
attention should be paid to the treatment of the original
comorbidities, especially in older patients with already severe
underlying conditions.
4. Association between COVID-19 and
diabetes
4.1. Diabetes and Infection: General considerations and
potential mechanisms
Diabetes is one of the leading causes of morbidity and mortal-
ity throughout the world. The condition is associated with
several macrovascular and microvascular complications, that
ultimately impact the overall patient’s survival [30]. A rela-
tionship between diabetes and infection has long been clini-
cally recognized [31]. Infections, particularly influenza and
pneumonia, are often common and more serious in older
people with type 2 diabetes mellitus (T2DM) [32,33]. Neverthe-less, the evidence remains controversial regarding whether
diabetes itself indeed increases susceptibility and impacts
outcomes from infections, or the cardiovascular and renal
comorbidities that are frequently associated with diabetes
are the main factors involved [34].
Diabetes and uncontrolled glycaemia were reported as sig-
nificant predictors of severity and deaths in patients infected
with different viruses, including the 2009 pandemic influenza
A (H1N1) [35], SARS-CoV [36] and MERS-CoV [37]. In the cur-
rent SARS-CoV-2 pandemic, some studies did not find a clear
association between diabetes and severe disease [19,38]. How-
ever, other reports from China [7,20] and Italy [29] showed
that older patients with chronic diseases, including diabetes,
were at higher risk for severe COVID-19 and mortality.
Scarce data exist regarding glucose metabolism and devel-
opment of acute complications of diabetes (e.g., ketoacidosis)
in patients with COVID-19. Infection of SARS-CoV-2 in those
with diabetes possibly triggers higher stress conditions, with
greater release of hyperglycemic hormones, e.g., glucocorti-
coids and catecholamines, leading to increased blood glucose
levels and abnormal glucose variability [39]. On the other
hand, a retrospective study fromWuhan reported that around
10% of the patients with T2DM and COVID-19 suffered at least
one episode of hypoglycemia (<3.9 mmol/L) [40]. Hypo-
glycemia has been shown to mobilize pro-inflammatory
monocytes and increase platelet reactivity, contributing to a
higher cardiovascular mortality in patients with diabetes
[41]. Yet it remains largely unknown how exactly the inflam-
matory and immune response occurs in these patients, as
well as whether hyper- or hypoglycemia may alter the
SARS-CoV-2 virulence, or the virus itself interferes with insu-
lin secretion or glycemic control. Furthermore, the impact of
usual diabetes drug treatment on COVID-19 outcomes, as well
as therapeutic approaches for COVID-19 on glucose regulation
remains unspecified.
Diabetes is a chronic inflammatory condition character-
ized by multiple metabolic and vascular abnormalities that
can affect our response to pathogens [34]. Hyperglycemia
and insulin resistance promote increased synthesis of glyco-
sylation end products (AGEs) and pro-inflammatory cytoki-
nes, oxidative stress, in addition to stimulating the
production of adhesionmolecules that mediate tissue inflam-
mation [34,42]. This inflammatory process may compose the
underlying mechanism that leads to a higher propensity to
infections, with worse outcomes thereof in patients with dia-
betes [34].
Several defects in immunity have been associated with
hyperglycemia, even though the clinical relevance of some
in vitro disturbances are still not fully understood [43]. Poorly
controlled diabetes has been linked to inhibited lymphocyte
proliferative response to different kinds of stimuli [44], as well
as impaired monocyte/macrophage and neutrophil functions
[34]. Abnormal delayed type hypersensitivity reaction [43] and
complement activation dysfunction [45] have also been
described in patients with diabetes. In vitro studies have
shown that pulmonary epithelial cells exposure to high glu-
cose concentrations significantly increases influenza virus
infection and replication, indicating that hyperglycemia may
enhance viral replication in vivo [46]. In animal models, struc-
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mented vasculature permeability and collapsed alveolar
epithelium [47]. On the other hand, patients with diabetes
generally present a significant reduction in forced vital capac-
ity (FVC) and forced expiratory volume in one second (FEV1),
which is associated with raised plasma glucose levels [48].
4.2. Aspects of SARS-CoV-2 pathogenesis and potential
implications for clinical management of patients with COVID-
19 and diabetes
Patients with COVID-19 commonly show on admission lym-
phocytopenia, and to a lesser extent thrombocytopenia and
leukopenia, which are more prominent among those with
severe disease [7]. Further, elevated levels of pro-
inflammatory cytokines, including interleukin-6 (IL-6) and
C-reactive protein, as well as increased coagulation activity,
marked by higher d-dimer concentrations, were also associ-
ated with severity [7,26]. In T2DM, besides the marked inflam-
matory process previously discussed, an imbalance between
coagulation and fibrinolysis takes place, with increased levels
of clotting factors and relative inhibition of the fibrinolytic
system. Both insulin resistance and T2DM are associated with
endothelial dysfunction, and enhanced platelet aggregation
and activation. These abnormalities favor the development
of a hypercoagulable pro-thrombotic state [49]. Additionally,
atherosclerosis, vascular inflammation and endothelial dys-
function are also part of the pathogenesis of other chronic
conditions, e.g., hypertension and CVDs [42]. Animal studies
involving SARS-CoV reported that older age was related to
defects in T-cell and B-cell function and excess inflammation
markers. Thus, T2DM alone or in association with older age,
hypertension and/or CVDs might contribute to a deficient
control of SARS-CoV-2 replication and more prolonged proin-
flammatory response, potentially leading to poor outcomes
[26].
Viral entry into the host cells is a fundamental component
of cross-species transmission, particularly for the coron-
aviruses (CoVs). Upon exposure of the host to the virus, all
CoVs, through a Spike protein, bind to cells that express
specific receptors. After binding to the target cells, the host-
cell protease cleaves the spike, which allows the virus to enter
and replicate [50]. The angiotensin-converting enzyme 2
(ACE2) has been identified as one of the main receptors for
both SARS-CoV [51] and SARS-CoV-2 [50]. ACE2 is widely
expressed on the respiratory tract, heart, kidneys, intestines,
cerebral neurons, endothelium of arteries and veins, immune
cells and pancreas [2]. A Chinese study compared 39 SARS-
CoV patients without previous diabetes, who did not receive
steroid treatment, with 39 matched healthy siblings and
showed that 20 of the 39 SARS-CoV patients developed dia-
betes during hospitalization. Since immunostaining for
ACE2 was strong in the pancreatic islets, it was suggested that
SARS-CoV might have damaged islets and caused acute insu-
lin dependent diabetes mellitus [52]. Therefore, although fur-
ther evidence is needed, pancreatic damage may also be
present in COVID-19 patients, possibly contributing to worse
outcomes in subjects with diabetes.
Previous studies have reported decreased mortality and
endotracheal intubation in patients with viral pneumoniawho were in continued use of ACE inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) [53,54]. These medica-
tions are postulated to have significant immunomodulatory
effects [55] and reduce pulmonary and systemic inflamma-
tory response by decreasing cytokines [53,54]. They are com-
monly used by those with diabetes and hypertension [56],
therefore, their impact on the clinical course of COVID-19
has been widely debated. Considering that ACE2 is a func-
tional receptor for SARS-CoV-2 and its levels can be increased
by ACEIs and ARBs, it has been argued that these drugs might
affect negatively the outcome of COVID-19 patients [57]. On
the contrary, some have advocated that ACEIs and ARBs
might rather be beneficial [58]. SARS-CoV infection and the
virus Spike protein reduce ACE2 expression. Mice injected
with SARS-CoV Spike presented worsened acute lung failure,
which could be attenuated by blocking the renin-angiotensin
pathway [59]. Nevertheless, a retrospective analysis per-
formed on 112 patients with COVID-19 and CVD did not show
a significant difference in the proportion of ACEI/ARBmedica-
tion between survivors and non-survivors [60]. Similar to
ACEIs and ARBs, ibuprofen [61] and thiazolidinediones [62]
can also result in increased levels of ACE2, thus generating
questions regarding the safety of these drugs in patients with
COVID-19.
Although diabetes has been associated with worse out-
comes in COVID-19 patients, the susceptibility to SARS-CoV-
2 infectionmay not be higher in people with diabetes. Accord-
ing to several studies, the prevalence of diabetes in people
infected with the virus is about the same as in the general
population, even slightly lower [28,63]. A meta-analysis of 12
studies describing data from 2,108 Chinese patients with
COVID-19 reported a diabetes prevalence of 10.3% [63], which
was similar to the national prevalence of 10.9% reported in
2013 [64]. An Italian study conducted among 146 patients with
confirmed SARS-CoV-2 infection at the University Hospital of
Padova found an equivalent pattern. The prevalence of dia-
betes in these patients was 8.9% (mean age 65.3 years), while
it was 11.0% among people aged 55–75 years (mean age
65 years) from the same region in 2018 [65]. Although under-
reporting may be an issue to consider, potential biological
mechanisms should not be disregarded. It has been shown
that dipeptidyl peptidase-4 (DPP-4) is the primary receptor
of MERS-CoV [2]. Since DPP-4 inhibitors are commonly
applied in the treatment of diabetes worldwide, future
research should explore whether DPP-4 may also act as recep-
tor for SARS-CoV-2, thus contributing to a potential protective
effect of these drugs against COVID-19 [63,66].
So far, no anti-SARS-CoV-2 drug or vaccine has been offi-
cially approved for COVID-19 treatment [67]. Several clinical
trials are in progress to assess the safety and efficacy of
potential treatment alternatives, including remdesivir, tocili-
zumab, lopinavir/ritonavir, ribavirin, interferon, chloroquine
phosphate, arbidol, among others [68]. One promising phar-
macological option of relevance for patients with diabetes is
chloroquine and its hydroxy-analogue hydroxychloroquine.
Widely used for malaria and autoimmune diseases, chloro-
quine has also been reported as a potential broad-spectrum
antiviral drug. Although the efficacy and safety of chloroquine
for COVID-19 treatment remain unclear, a recent study
showed that the drug was highly effective in controlling
6 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 2 ( 2 0 2 0 ) 1 0 8 1 4 2SARS-CoV-2 infection in vitro. In addition to its immunomod-
ulant and anti-inflammatory effect, chloroquine increases
endosomal pH and interferes with the glycosylation of cellu-
lar receptors of SARS-CoV, thereby blocking viral infection
[69]. Preliminary results frommore than 100 patients included
in a Chinese clinical trial showed that chloroquine was supe-
rior to the control group in shortening the disease course,
inhibiting pneumonia exacerbation, promoting a virus nega-
tive conversion and radiological improvement without severe
side effects [70]. On the other hand, several studies have
reported that hydroxychloroquine improves glycemic control
in decompensated, treatment-refractory patients with dia-
betes [71,72]. It has even been approved to treat T2DM in India
as an add-on therapy for patients who do not achieve glyce-
mic targets with two other oral glucose-lowering drugs [73].
Although inflammation is associated with impaired glucose
control, the underlying mechanism of hydroxychloroquine’s
hypoglycemic effect remains unclear [71]. It has been
described that chloroquine increases the C peptide response,
potentially reflecting an improved pancreatic b-cell function
[72]. Reduced intracellular insulin degradation and increased
insulin accumulation have also been identified as possible
effects of hydroxychloroquine in animals models [74]. Given
the previously reported impact of chloroquine/hydroxychloro
quine on glucose metabolism, caution should be taken when
the drug is administered to patients with diabetes and COVID-
19. A dose adjustment of the oral antidiabetic drugs and/or
insulin might be necessary in order to prevent potential hypo-
glycemic events.
The effect of corticosteroids on COVID-19 is also under
investigation [68]. Acute lung damage and ARDS are partly
due to the host immune response. While corticosteroids sup-
press lung inflammation, they also inhibit immunity and
pathogen clearance [75]. In SARS-CoV and MERS-CoV infec-
tions, pulmonary histology showed inflammation and diffuse
alveolar damage [76]. Therefore, corticosteroids were broadly
applied [77,78]. However, evidence did not show benefits,
rather it was reported delayed viral RNA clearance or
increased mortality and rate of complications, including dia-
betes, psychosis, and avascular necrosis [75]. The interim
guidance from the WHO on clinical management of severe
acute respiratory infection when SARS-CoV-2 infection is sus-
pected advises against the use of corticosteroids outside clin-
ical trials [79]. Considering the hyperglycemic effect [80] and
the impact of these drugs on the immune response [75], spe-
cial caution should be taken in patients with diabetes
included in trials assessing the safety and efficacy of corticos-
teroids for COVID-19 [80].
No data is available regarding the most appropriate man-
agement of patients with diabetes infected by SARS-CoV-2,
as well as patients with COVID-19 who develop glycemic
decompensation. Rigorous glucose monitoring and careful
consideration of drug interactions might attenuate worsening
of symptoms and adverse outcomes. Although hyperglycemia
is usually the main concern in this context, one should not
disregard the possibility of hypoglycemic episodes as a result
of the interplay between drug treatment, viral pathogenesis
and typical metabolic disturbances of diabetes. Patient tai-
lored therapeutic strategies and optimal glucose control goals
should be formulated based on disease severity, presence ofcomorbidities and diabetes-related complications, age and
other factors. A multidisciplinary team approach, including
infectologists, endocrinologists, pulmonologists, psycholo-
gists, nutritionists and exercise rehabilitation specialists
may be necessary during the prolonged hospitalization peri-
ods and recovery. Special attention should be paid to those
with diabetic nephropathy, or diabetes-related heart compli-
cations, since they are also at higher risk for severe COVID-
19 and death [7,19]. Finally, increased vigilance and testing
in outpatient diabetes clinics for COVID-19, as well as lower
thresholds for hospitalization of these patients may have a
positive impact on their outcomes.
5. Conclusions
COVID-19 has rapidly spread since its initial identification in
Wuhan and has shown a broad spectrum of severity. Early
isolation, early diagnosis, and early management might col-
lectively contribute to a better control of the disease and out-
come. Diabetes and other comorbidities are significant
predictors of morbidity and mortality in patients with
COVID-19. Future research is urgently needed to provide a
better understanding regarding potential differences in
genetic predispositions across populations, underlying patho-
physiological mechanisms of the association between COVID-
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